Drug intelligence / Profile preview

autologous cd34-selected peripheral blood stem cells

Development stage: Phase 2
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

Autologous CD34-selected peripheral blood stem cells are a population of hematopoietic progenitor cells expressing the surface marker CD34, collected from a patient’s own (autologous) peripheral blood. These cells are used primarily in autologous hematopoietic stem cell transplantation (ASCT) procedures. The process involves mobilizing the patient’s own stem cells into the bloodstream using agents such as cyclophosphamide and granulocyte colony-stimulating factor (G-CSF), collecting them via leukapheresis, selecting for CD34+ expression using devices like Isolex 300 or CliniMACS, and then reinfusing them after high-dose chemotherapy or other conditioning regimens to reconstitute the immune system[1][2]. This approach is being evaluated for diseases such as multiple sclerosis and other autoimmune disorders where immune system reset is desired[2][3].

Brand names: CliniMACS CD34-Selected Cells
Other names: autologous CD34-positive peripheral blood stem cellsautologous hematopoietic stem cell transplantation (when used as therapy)CD34+ selected ASCT

Beyond the preview

Go deeper on autologous cd34-selected peripheral blood stem cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous cd34-selected peripheral blood stem cells.

Explore the full profile